Cangrelor
As of the edition of 20 October 2026, Cangrelor is a small molecule: marketed, first approved in 2015 (EU); acts on P2RY12.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Small molecule
- Brand name
- Kengreal
- First approved
- 23 March 2015 (EU)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Chiesi Farmaceutici; 2 holders in all
- Registered trials
- 27, 4 stopped early
- Disease areas
- Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| P2RY12 | P2Y purinoceptor 12 | Q9H244 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 2 | 0 | 1 |
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 7 | 4 | 1 | 0 |
| Phase 3 | 3 | 0 | 1 | 2 |
| Phase 4 | 10 | 7 | 2 | 1 |
| All trials | 27 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novartis | Applicant and Lead sponsor of trials | 2005 to now |
| Chiesi Farmaceutici | Applicant and Lead sponsor of trials | 2015 to now |
| Chiesi | Acquired holder | 2016 to now |